Abstract: One hundred and eighteen patients of stage Ⅱ B / Ⅲ B cervical cancer were treated in our hospital between 1990 and 1992, an unradomized trial was designed to evaluate carboplatin as a radiosensitizer in advanced cervical cancer, research group 68 cases (squamous carcinoma 63 cases, adnocarcinoma 5 cases), control group 50 cases (squamous carcinoma 47 cases, adnocarcinoma 3 cases), patients of research group received intravenous carboplatin in the morning at the dose 50mg, brachtherapy was administered in the afternoon, the total dose is 400～500mg. The 5 year survival rate is 66 1%(45/68) and 66%(33/50) ( P 0 05), there is no significant difference. The reason may be as follows: 1.carboplatin administered once a week made concentration of blood can't be constant; 2.the dose was too low; 3.the period between carboplatin intravenous and brachtherapy was too long. Besides, therotically chemotherapy can make residual tumor cell accelerate reproduction and clone reconstitute. The problem remains to be resolved in clinic: 1.select effective dose and reduce endurable side effect; 2.the suitable time to give carboplatin; 3.the proper order between carboplatin and brachtherapy.